JPRN-UMIN000008470RecruitingPhase 2
Post remission therapy with arsenic trioxide and gemtuzumab ozogamicin in acute promylocytic leukemia, a phase II study (JALSG APL212 Study) - Post remission therapy with arsenic trioxide and gemtuzumab ozogamicin in acute promylocytic leukemia (JALSG APL212)
the Japan Adult Leukemia Study Group (JALSG)0 sites222 target enrollmentStarted: July 19, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 222
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 15years-old to 64years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. History of myelodysplastic syndrome 2. Atypical acute leukemia 3. Uncontrollable infection 4. Severe co-morbidity 5. Positive anti-HIV antibody, HBs antigen or anti-HCV antibody 6. Other active neoplasm 7. Pregnant and/or lactating woman 8. Psychological disorders 9. Patients who have a difficulty to enter the study.
Investigators
Similar Trials
Recruiting
Phase 2
Post remission therapy including arsenic trioxide against acute promylocytic leukemia over 65 years old, Phase II Clinical Study (JALSG APL212G study)Adult acute promylocytic leukemiaJPRN-UMIN000008471the Japan Adult Leukemia Study Group (JALSG)63
Not yet recruiting
Phase 4
Clinical efficacy of arsenic trioxide combined with carboplatin for neoadjuvant chemotherapy for locally advanced cervical cancerCervical cancerITMCTR1900002399The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Completed
Phase 2
Post remission therapy with arsenic trioxide and gemtuzumab ozogamicin in acute promylocytic leukemia (JALSG APL212)JPRN-jRCTs041180100Takeshita Akihiro218
Withdrawn
Phase 2
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Recurrent Adult Acute Myeloid LeukemiaNCT01835288Stanford University
Completed
Phase 2
Arsenic Trioxide in Treating Patients With Urothelial CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerTransitional Cell Carcinoma of the BladderUreter CancerNCT00009867National Cancer Institute (NCI)35